Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments.
Poly(ethylene glycol)-dextran (PEG-DEX) conjugates have been used as a combined stabilizer and surface modifier to produce resorbable poly(DL-lactide-co-glycolide) (PLG) microparticles by an emulsification/solvent evaporation technique. The use of PEG or dextran polymers alone was incapable of producing microparticles. Particle size measurements revealed smaller mean particle sizes (480 nm) and improved polydispersity when using a 1.2% PEG substituted conjugate relative to a 9% substituted material (680 nm). PLG microparticles modified by post-adsorbed PEG-DEX conjugates flocculated in 0.01 M salt solutions, whereas PLG microparticles prepared using PEG-DEX as a surfactant were stable in at least 0.5 M NaCl solutions. Surface modification of PLG microparticles was confirmed by zeta potential measurements and surface analysis using X-ray photoelectron spectroscopy. The presence of surface exposed dextran was confirmed by an immunological detection method using a dextran-specific antiserum in an enzyme-linked immunosorbent assay. The findings support a model in which the PEG component of the PEG-DEX conjugate provides an anchor to the microparticle surface while the dextran component extends from the particle surface to contribute a steric stabilization function. This approach offers opportunities for attaching hydrophilic species such as targeting moieties to biodegradable microparticles to improve the interaction of drug carriers and vaccines with specific tissue sites.
Coombes
A G
AG
Department of Pharmaceutical Sciences, University of Nottingham, University Park, UK.
Tasker
S
S
Lindblad
M
M
Holmgren
J
J
Hoste
K
K
Toncheva
V
V
Schacht
E
E
Davies
M C
MC
Illum
L
L
Davis
S S
SS
D001672:Biocompatible Materials / Q000737:chemistry / Q000378:metabolism*; D003911:Dextrans / Q000737:chemistry / Q000378:metabolism*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004355:Drug Stability; D004655:Emulsions; D004797:Enzyme-Linked Immunosorbent Assay; D019344:Lactic Acid / Q000378:metabolism*; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism*; D011100:Polyglycolic Acid / Q000378:metabolism*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000378:metabolism*; D012997:Solvents; D013052:Spectrometry, X-Ray Emission; D013499:Surface Properties; D014612:Vaccines / Q000008:administration & dosage*; D014835:Volatilization
D001672:Biocompatible Materials; D003911:Dextrans; D004337:Drug Carriers; D004655:Emulsions; D011108:Polymers; D012997:Solvents; D014612:Vaccines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols